CAMP
CAMP4 THERAPEUTICS CORPORATION Healthcare - Biotechnology Investor Relations →
CAMP4 THERAPEUTICS CORPORATION (CAMP) closed at $4.13 as of 2026-06-19, trading 2.6% below its 200-week moving average of $4.24. This places CAMP in the below line zone. The stock is currently moving closer to the line, down from -1.2% last week. With a 14-week RSI of 29, CAMP is in oversold territory.
A big spike in selling this week — 3.0x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.
Over the past 40 weeks of data, CAMP has crossed below its 200-week moving average 5 times. On average, these episodes lasted 3 weeks.
With a market cap of $214 million, CAMP is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -209.3%. The stock trades at 6.9x book value.
Share count has increased 166.1% over three years, indicating dilution.
In the past 12 months, corporate insiders have made 7 open-market purchases totaling $15,563,424. Multiple insiders purchased within a 30-day window — a cluster buy pattern that historically signals management confidence in the company's prospects. Notably, these purchases occurred while CAMP is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. CAMP currently has negative free cash flow, so price-based dislocation levels are not available. The score still tracks yield deviation from baseline.
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from CAMP's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
CAMP has crossed below its 200-week MA 5 times
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Sep 2025 | Oct 2025 | 6 | 44.9% | N/A | +81.1% |
| Nov 2025 | Dec 2025 | 3 | 28.3% | N/A | +42.4% |
| Jan 2026 | Feb 2026 | 4 | 11.9% | N/A | +3.0% |
| Apr 2026 | May 2026 | 1 | 4.4% | N/A | +2.0% |
| Jun 2026 | Ongoing | 3+ | 3.1% | Ongoing | +0.5% |
Frequently Asked Questions
Is CAMP below its 200-week moving average?
Yes. As of 2026-06-19, CAMP4 THERAPEUTICS CORPORATION (CAMP) is trading 2.6% below its 200-week moving average of $4.24. The current price is $4.13.
What is CAMP's 200-week moving average price?
CAMP4 THERAPEUTICS CORPORATION's 200-week moving average is $4.24 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when CAMP drops below its 200-week moving average?
CAMP has crossed below its 200-week moving average 5 times in our data. These episodes lasted 3 weeks on average.
Is CAMP a good value right now?
Here's what our data says about CAMP as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 29 (oversold). Free cash flow is currently negative. Return on equity is -209.3%. Price-to-book is 6.9x. This is not a buy or sell recommendation — always do your own research.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19